Angiotensin I (human, mouse, rat): Sequence, Mechanism, and RAS Research Applications

Executive Summary: Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) is a decapeptide generated from angiotensinogen via renin cleavage and is the direct precursor of angiotensin II, a potent vasoconstrictor (Oliveira et al., 2025). While Angiotensin I lacks direct biological activity, its conversion by angiotensin-converting enzyme (ACE) to angiotensin II underpins key cardiovascular regulatory mechanisms. The APExBIO A1006 product offers high-purity, sequence-defined Angiotensin I for reproducible renin-angiotensin system (RAS) research (APExBIO). Experimental workflows using Angiotensin I enable robust screening of antihypertensive agents and mechanistic studies of Gq protein-coupled receptor activation. The peptide's physicochemical properties, storage requirements, and solubility parameters are well established, supporting its broad application in cardiovascular and neuroendocrine models.

Biological Rationale

Angiotensin I (human, mouse, rat) is a linear decapeptide with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH. It is produced by the action of renin on angiotensinogen, a plasma globulin synthesized in the liver (DOI). Angiotensin I itself is biologically inactive but serves as the essential precursor to angiotensin II, which is the principal effector peptide of the renin-angiotensin system (RAS). The RAS is a tightly regulated endocrine cascade involved in blood pressure homeostasis, fluid balance, and electrolyte regulation (Angiotensin I: Core Mechanisms). Angiotensin I thus occupies a critical position in cardiovascular physiology, with its conversion to angiotensin II representing a rate-limiting step for downstream signaling.

Mechanism of Action of Angiotensin I (human, mouse, rat)

Angiotensin I is generated when renin cleaves angiotensinogen between Leu10 and Val11, yielding the decapeptide (1–10) form. Angiotensin-converting enzyme (ACE), primarily located on endothelial cell surfaces, cleaves Angiotensin I between His9 and Leu10, producing angiotensin II (1–8) (DOI). Angiotensin II then binds to type 1 angiotensin II receptors (AT1R), a Gq protein-coupled receptor (GPCR). This interaction activates phospholipase C, generating inositol trisphosphate (IP3), which mobilizes intracellular calcium and triggers vasoconstriction. The pathway is central to the regulation of systemic vascular resistance and blood pressure (Molecular Precursor article). Angiotensin I's lack of direct receptor binding or signaling underscores its role as a biochemical intermediate rather than an effector molecule.

Evidence & Benchmarks

• Angiotensin I (1–10) is formed by renin cleavage of angiotensinogen in the liver; the decapeptide sequence is Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu (Oliveira et al., Fig. 1).
• ACE converts Angiotensin I (1–10) to Angiotensin II (1–8) by removing the C-terminal His-Leu dipeptide (Oliveira et al., Methods).
• Angiotensin I does not bind to AT1R or AT2R and is considered biologically inactive until conversion (Oliveira et al., Results).
• Intracerebroventricular injection of Angiotensin I in animal models increases fetal blood pressure and activates hypothalamic arginine vasopressin (AVP) neurons, confirming its suitability for neuroendocrine research (APExBIO).
• Angiotensin I is highly soluble (>129.6 mg/mL in DMSO, >124.2 mg/mL in water, >9.16 mg/mL in ethanol), facilitating high-concentration experimental setups (APExBIO, Technical Data).
• Angiotensin peptides, including Angiotensin I, have no direct effect on SARS-CoV-2 spike-AXL binding, whereas shorter fragments (e.g., Ang IV) do enhance binding (Oliveira et al., Table 1).

Applications, Limits & Misconceptions

Angiotensin I (human, mouse, rat) is extensively employed in basic and translational research targeting the renin-angiotensin system. Its applications include:

• Screening and validation of antihypertensive drugs that target RAS enzymes or receptors.
• Modeling cardiovascular disease mechanisms, including hypertension and heart failure (Reliable Solutions article—this article expands by providing new evidence benchmarks and emphasizing experimental parameters).
• Dissecting neuroendocrine regulation via central administration in animal models.
• Investigating Gq protein-coupled receptor signaling pathways in smooth muscle and neuronal systems.

Common Pitfalls or Misconceptions

• Assuming Angiotensin I has direct vasoconstrictive or receptor-mediated activity—only Angiotensin II (and certain fragments) do (DOI).
• Misapplying Angiotensin I in SARS-CoV-2 spike protein binding studies—Angiotensin I does not enhance spike-AXL binding, unlike some shorter peptides (DOI).
• Overlooking storage and solubility requirements; improper handling can lead to degradation or precipitation (APExBIO).
• Confusing the mechanism: Angiotensin I is a substrate, not a ligand for AT1R/AT2R (Molecular Precursor article—this clarifies the receptor specificity relative to previous guides).
• Assuming all species have identical sequence or activity—verify homology for cross-species studies.

Workflow Integration & Parameters

APExBIO's Angiotensin I (SKU: A1006) is provided as a lyophilized solid, with a molecular weight of 1296.5 Da. It is stable when stored desiccated at -20°C and shipped on blue ice. Solubility is documented as >129.6 mg/mL in DMSO, >124.2 mg/mL in water, and >9.16 mg/mL in ethanol. Experimental use includes:

• Preparation of stock solutions in DMSO or water for cell-based and in vivo assays.
• Intracerebroventricular injection in animal models for monitoring blood pressure or AVP neuron activation.
• Benchmarking against known RAS modulators in screening workflows (Experimental Workflows article—this article adds detailed solubility and storage specifications).
• Comparative sequence analysis with other angiotensin peptides to inform structure-activity studies.

See the product page for ordering and latest batch-specific details.

Conclusion & Outlook

Angiotensin I (human, mouse, rat) remains the definitive biochemical precursor for dissecting the RAS, enabling precise mechanistic, pharmacological, and translational research. While its direct biological activity is minimal, its conversion to angiotensin II is a cornerstone of cardiovascular regulation. The APExBIO A1006 kit provides validated, high-purity Angiotensin I for reproducible workflows. Future directions include advanced applications in combinatorial RAS modulation, disease model refinement, and expanded neuroendocrine research. For further technical guidance, users may consult recent method guides (Advanced RAS Research article—this article updates with quantitative solubility and handling data not previously detailed).